![]() The FDA approved Rybelsus, the first oral GLP-1 receptor agonist drug, in September 2019. ![]() These work by simulating the actions of GLP-1 receptors in the pancreas, increasing insulin release while decreasing the glucagon release response, both of which are glucose-dependent, thereby, lowering blood sugar levels. Rybelsus and Ozempic are incretin mimetic agents that are used in combination with diet and exercise to help adults with type 2 diabetes control their blood sugar levels. Your health status (such as the presence of other comorbidities) and preference will be considered when prescribing either of these drugs. If your blood sugar is not responding well to other diabetes medications, your health care provider may add these drugs to your treatment regimen. Both have been approved by the Food and Drug Administration (FDA) to control blood sugar levels in adults with type 2 diabetes. ![]() Rybelsus and Ozempic are both brand names for a drug called semaglutide, their active ingredient, however both have a different form of delivery. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |